ADS-TEC-ENERGY-GMBH
ADS-TEC Energy today announced that ChargePost has won a German Innovation Award in the category Excellence in Business to business: E-Mobility Technologies, recognizing its design, brand, and innovation. ChargePost is a battery-buffered fast charging station developed and produced in Germany that enables off-grid ultra-fast charging of EVs within minutes. In a statement, the jury said, "With the ChargePost fast charging station from ADS-TEC Energy, long waiting times when charging electric cars are a thing of the past, as the system always maintains a high charging capacity thanks to the buffer battery. In this way, ChargePost offers off-grid charging within a few minutes, which is particularly attractive for fleet vehicles and company parking lots, but also for supermarkets and other businesses with parking spaces. Two large HD screens positioned on the sides attract attention and offer striking opportunities for advertising and information. ChargePost is an attractive solution for the B2B sector thanks to the fact that the versatile station, which can be used in a wide variety of ways thanks to its low infrastructure requirements, can be supplied with alternative PV power and can be operated in many directions from the battery storage system. A meaningful innovation through unique and electrifying integration, further paving the way for e-mobility."
The German Innovation Awards recognize products, projects and pioneering achievements that improve life sustainably through innovation and progress. It was established by the German Bundestag and is sponsored by German industry.
There are already hundreds of ChargePost fast-charging points across Europe. It includes an integrated battery storage system to store energy which can then be used to boost charging power as required. This unique battery technology makes it possible to charge up to 300 kW even on a power-limited grid. Busy charging locations have proven that dozens of vehicles can be fast-charged in one day and that ChargePost can achieve over 1 MW per day. With these features, ChargePost eliminates the expensive, time-consuming, and resource-intensive network expansion that is necessary for a traditional charging station.
ChargePost also gives infrastructure operators new revenue opportunities. If, for example, self-generated PV electricity is used for charging, the energy procurement costs for the operators are reduced, bucking the trend of constantly rising grid charges. Another option is that operators can use ChargePost’s bidirectional battery to cap peak loads or feed back into the grid. And, by linking several ChargePosts to form a virtual power plant, the operator can start trading energy and benefit from volatile electricity prices. These features make the solution sustainable as well as bringing charging in just minutes to places where it would otherwise not be possible, for example in rural areas far away from highways, charging parks, or city centers.
About ADS-TEC Energy
ADS-TEC Energy plc, a public limited company incorporated in Ireland and publicly listed on NASDAQ (“ADS-TEC Energy”), serves as a holding company for ADS-TEC Energy GmbH, our operating company incorporated in Germany (“ADSE GM”) and ADS-TEC Energy Inc., a US subsidiary of ADS-TEC Energy GmbH (“ADSE US” and together with ADS-TEC Energy and ADSE GM, “ADSE”). Based on more than ten years of experience with lithium-ion technologies, ADS-TEC Energy develops and manufactures battery storage solutions and fast charging systems including their energy management systems. Its battery-based, fast charging technology enables electric vehicles to ultrafast charge even on low powered grids and features a very compact design. It was most recently nominated by the President of the Federal Republic of Germany for the German Future Prize and elevated to the "Circle of Excellence" in 2022. The high quality and functionality of the battery systems are due to a particularly high depth of development and in-house production. With its advanced system platforms, ADS-TEC Energy is a valuable partner for automotive, OEMs, utility companies and charge-operators.
Image link: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=download2_file&code_str=91bfd4aa009ee1f8469b91eef5b216f3
More information: www.ads-tec-energy.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240515597863/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
EADV 2025: Almirall Advances Skin Science and Leads Innovation for Holistic Patient Care in Medical Dermatology17.9.2025 08:57:00 CEST | Press release
Almirall’s scientific presence at the 34th EADV congress reflects its broad portfolio of dermatological treatments and patient-centric approach - featuring 44 abstracts, two expert-led symposia on atopic dermatitis and psoriasis, and an interactive booth. Lebrikizumab’s effectiveness in the treatment of moderate-to-severe atopic dermatitis is demonstrated by new real-world evidence, and long-term efficacy and patient well-being data. New real-world data demonstrate tildrakizumab’s effectiveness in the treatment of psoriasis in high-impact areas of the body and across multiple patient groups - particularly elderly patients and those with high disease burden. Almirall’s pipeline progress includes new initial phase 1 data on a developmental treatment for Hidradenitis Suppurativa (HS), LAD191 a monoclonal antibody targeting the Interleukin-1 Receptor Accessory Protein (IL-1RAP) shows preliminary signs of clinical symptom improvements, and a favourable safety and tolerability profile. Almir
SES delivered unprecedented MEO satellite connectivity for French Navy’s Clemenceau 25 mission17.9.2025 08:50:00 CEST | Press release
During international operations, SES’s high-throughput low-latency Medium Earth Orbit (MEO) managed satcom service provided connectivity to flagship aircraft carrier Charles de Gaulle of the French Carrier Strike Group (GAN) SES announced today that the French Navy’s aircraft carrier Charles de Gaulle leveraged its secure and reliable O3b mPOWER satcom service – Managed Naval mPOWERED – during the Clemenceau 25 mission. This high-throughput, low-latency Medium Earth Orbit (MEO) connectivity solution supported all of the aircraft carrier’s operations, while facilitating collaboration with mission partners. During the five-month deployment, the French Carrier Strike Group (GAN) covered 40,000 nautical miles and conducted various exercises and joint activities with around twenty allied nations. The connectivity provided by SES ensured optimal performance and uninterrupted operational availability for the aircraft carrier’s mission-critical applications. Thanks to the global reach, reliabi
Deepfakes Already Hitting Businesses as Often as Traditional Fraud, Regula Survey Finds17.9.2025 08:00:00 CEST | Press release
Fresh survey data from Regula, a global developer of identity verification (IDV) solutions and forensic devices, shows that the line between traditional fraud and impersonation attacks has vanished. Identity spoofing, biometric fraud, and AI-powered deepfakes have already struck one in three organizations worldwide, catching up with long-standing fraud tactics like forged documents and social engineering. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250916314726/en/ Regula’s survey shows that impersonation attacks overtake traditional fraud schemes. Three impersonation-driven tactics now dominate the fraud playbook, each exploiting weaknesses in verification: Identity spoofing (reported by 34% of organizations) — Holding up a printed photo, replaying a video, or showing a screen image to a camera. Often used to mass-open accounts for scams or mule networks. Biometric fraud (34%) — Physical deceptions like fake fingerprints
Overture Life Launches European Preorder Waitlist for DaVitri, the World’s First Microfluidics-Based Automated Vitrification Platform17.9.2025 07:00:00 CEST | Press release
Ahead of receipt of anticipated CE Mark, European customers can begin requesting DaVitri to expand patient access to high-quality IVF Overture Life, the innovator modernizing IVF to optimize reproductive freedom, today announced the launch of its European preorder waitlist for DaVitri, the world’s first automated vitrification platform. The waitlist ensures in vitro fertilization (IVF) facilities will be among the first in Europe to harness DaVitri to reduce manual workloads for their embryologists while eliminating operator variability, thereby providing patients with faster, more consistent procedures. As infertility rates spike worldwide, interest in egg freezing continues to rise while the infrastructure to support it lags behind. Egg freezing requires vitrification, typically a time-intensive, manual process vulnerable to human error that can only be performed by extensively trained embryologists. This has resulted in variability in egg and embryo survival rates that directly impa
Incyte Announces New 24-Week Phase 3 Data from the STOP-HS Clinical Trial Program of Povorcitinib in Hidradenitis Suppurativa at EADV 202517.9.2025 07:00:00 CEST | Press release
Across both STOP-HS1 and STOP-HS2, povorcitinib treatment resulted in continued clinically meaningful and statistically significant improvements for patients with active moderate to severe hidradenitis suppurativa (HS) through Week 24At Week 24, nearly 60% of efficacy-evaluable patients among both povorcitinib treatment groups achieved HiSCR50Additionally, patients treated with povorcitinib achieved HiSCR75 (31.0%-40.3%), HiSCR90 (13.8%-27.7%) and HiSCR100 (9.2%-21.3%) through Week 24Povorcitinib-treated patients also achieved greater improvements in skin pain by the first visit (Week 3) through Week 24 with 62%-70% achieving mild or no pain at Week 24 Incyte (Nasdaq:INCY) today announced new 24-week interim data evaluating the safety and efficacy of povorcitinib (INCB54707), an oral small-molecule highly-selective JAK1 inhibitor, from the pivotal Phase 3 STOP-HS clinical trial program in adult patients (≥18 years) with moderate to severe hidradenitis suppurativa (HS). These data will
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom